The Vaccine Debate Opened a Door.

Here's What's Behind It.

By Dr. Justin Dearing | The Dearing Clinic

When the executive order on vaccine scheduling landed last week, the reaction came fast and loud. One side called it long overdue. The other called it dangerous. Both sides went straight to the same argument they have been having for twenty years, and neither side said the thing that actually matters.

I want to talk about what is behind the door this debate just opened.

I vaccinated my children. My wife Lauren and I made that decision together, and I would make it again. I have seen what measles encephalitis does to a child. I also see 70 and 80-year-old patients in this practice who have carried the physical consequences of poliomyelitis for their entire lives, the muscle weakness, the chronic pain, the post-polio syndrome that resurfaces decades after the original infection. The diseases these vaccines prevent are real, and the damage they cause is real. I have no interest in returning to that world, and that is not what this article is about.

But I remember sitting in 2014, a relatively new parent and a practicing clinician, looking at the vaccine schedule and feeling genuinely uneasy. Not because of something I read online. Because of what was walking through my clinic door every week.

What I Was Seeing in 2014

Children and teenagers were coming in with neurological and developmental presentations that my professors had described as uncommon. By 2014, they were not uncommon. They were in my waiting room, referred by other providers because nobody had answers. Labs normal. MRIs normal. These children were not okay.

The PANDAS cases stand out most clearly in my memory. Facial tics. Repetitive movements. Sudden onset OCD behaviors in children who had no prior psychiatric history. Teenagers with severe anxiety that appeared within days of a strep infection, as if someone had flipped a switch. These were not gradual presentations. They were abrupt and specific and they did not match any of the standard explanations.

What PANDAS revealed, and what medicine was only beginning to accept at that time, is that the immune system can produce antibodies in response to a strep infection that then cross-react with tissue in the basal ganglia. The basal ganglia are essentially the brain's filter. They manage what signals get through, what behaviors get expressed, what movements get executed, and what thoughts get acted on. When antibodies interfere with that filter, the result is tics, compulsive behaviors, and the kind of anxiety that feels like it came from nowhere because, from the child's perspective, it did.

Peanut allergies had transformed every school cafeteria in America. Epipens were standard equipment where they had not existed a generation earlier. Neurodevelopmental diagnoses were rising in every category. Something about how early immune systems were being calibrated was producing a qualitatively different pattern of reactivity than we had seen in previous generations.

I was not opposed to vaccines. I was asking a different question. Did we have any reliable way to assess whether a given child's immune system was ready to receive and process multiple immune stimuli at a single clinic visit? Was there a clinical tool that could tell us something meaningful about immune readiness before we proceeded?

The answer was no. And it still is.

A Case That Puts This in Focus

I want to give you a concrete example of what happens when the immune system loses its precision, because the abstract version of this argument is easy to dismiss.

I recently got a neural antibody panel back on a 74-year-old patient. He came in with a cluster of problems that, on the surface, looked like the expected findings for a man his age. Balance problems. Visual disturbances that three ophthalmologists had evaluated without finding a structural explanation in the eye itself. A restless, painful quality in his legs that kept him from sleeping. Neck degeneration on imaging at multiple levels. The working assumption from prior providers was reasonable: arthritic spine, deconditioned muscles, the physical wear of seven decades. Treat the neck, strengthen the body, manage the pain.

Before we ran any specialized panels, we mapped his brain function using qEEG brain mapping. What it showed was a specific and recognizable pattern: a loss of timing and coordination across the longest pathways in the brain, worst in the tracts connecting the visual and balance processing regions. His visual cortex was not responding normally to incoming signals. His brain networks were not communicating with the precision they should. The qEEG made the functional problem visible and measurable. What it cannot tell you is where that dysfunction is coming from. It might be a fuel and energy production problem at the cellular level. It might be inflammation. It might be a toxic burden, a chronic infection, or in his case, an immune system producing antibodies against its own neural tissue. The brain map shows you the functional consequence. To find the origin, you have to look at the broader landscape: gut-immune function, organic acids testing for mitochondrial and metabolic markers, and neural antibody panels. In his case, all three were necessary to understand what was actually driving what we were seeing on the map.

The neural antibody panel told the origin story.

One of the antibodies on his panel targets a protein that maintains the structure of the fatty coating on nerve fibers, particularly the longest ones in the body and brain. That fatty coating is what gives nerve signals their speed and precision. Think of it as the insulation on an electrical wire. When that insulation is compromised along a long fiber, the signal degrades over distance. Short connections hold up. Long ones fail first.

His visual pathways are among the longest in the nervous system, running from the back of the eye all the way to the visual processing cortex at the rear of the brain. His visual cortex was not processing incoming signals correctly, and every eye specialist had already confirmed the eye itself was structurally fine. The problem was not in the eye. It was in the long pathway between the eye and the brain, and in how the visual cortex was responding. The antibody was the explanation nobody had gone looking for.

His balance system depends on the same kind of long-distance communication, connecting the inner ear, the cerebellum, and the spinal cord. That pathway was showing the same degradation. The restless, painful legs were the peripheral end of the same process, long nerve fibers losing the integrity of their protective coating and generating abnormal signals that no amount of neck treatment was going to fix.

His immune system had lost the precision to distinguish his own neural architecture from something worth targeting. From the outside, it looked like aging. The qEEG showed us the functional signature. The antibody panel showed us the mechanism.

There was a second finding on his panel worth mentioning. Antibodies directed at dopamine receptors. In the exam room, this man was not presenting with obvious movement problems or psychiatric symptoms. What he presented as, and I say this with both clinical accuracy and genuine affection, was a grumpy old man. Irritable. Socially withdrawn. Less emotionally flexible than he had apparently been for most of his life. His family had chalked it up to age and personality. But dopamine receptor interference does not always produce the overt movement and psychiatric features most physicians associate with dopamine system dysfunction. Sometimes it produces a gradual shift in emotional tone, motivation, and interpersonal warmth that looks indistinguishable from a personality change. Nobody looks for an immune mechanism behind that. Nobody had looked for one in him.

The Thread Back to Children

Now consider where that line of reasoning leads when you apply the same principle to a developing brain.

In PANDAS, the immune system produces antibodies that disrupt the brain's filter, the basal ganglia, in a child who was neurologically normal the week before. The mechanism is antibody-mediated interference with specific brain tissue. The result is specific, regional, and in some cases severe.

The overlap between PANDAS presentations and ADHD diagnoses is not coincidental. Attention dysregulation, impulsivity, and behavioral unpredictability are downstream of the same basal ganglia and frontal circuitry that PANDAS disrupts through immune mechanisms. Some percentage of children carrying an ADHD diagnosis are carrying an immune finding underneath it that nobody has measured.

The line from there to the autism spectrum is the one medicine has been slow to follow, but the mechanistic reasoning is consistent. RFK Jr., the Department of Health and Human Services, and ongoing FDA review processes have signaled that findings on the origins of autism and neurodevelopmental disorders are expected in September 2026. I do not know what those findings will say. What I can tell you is that I will be watching closely, and that I have a strong clinical suspicion about where the evidence will point.

Here is the mechanistic argument stated plainly:

A properly developing brain does not spontaneously begin losing function in specific, regionally organized ways without a cause. The immune system is the only biological system with the molecular specificity to target discrete regions, receptors, and structural proteins in a developing brain and produce the disruption patterns we observe across the autism spectrum. That is not a claim that vaccines cause autism. The evidence does not support that specific claim, and autism is the product of multiple converging factors. But the immune system has to be part of this picture. It is the only system that operates with that level of precision, that has documented access to the brain when barrier function is compromised, and that we know from PANDAS to autoimmune encephalitis to the 74-year-old man in my exam room is capable of producing exactly this kind of neurological disruption when its regulatory precision fails.

When an immune system, for whatever combination of reasons, generates antibodies that cross-react with developing neural tissue during a critical window of brain development, the downstream effects would be specific, regional, and in a rapidly developing brain, potentially lasting. That is the hypothesis worth investigating seriously. That is what I hope the September HHS announcements are pointing toward.

The Question Nobody Is Asking

The current debate, the executive order, the vaccine schedule, the public argument about how many shots at what age, is a population-level conversation. Schedules are population tools. They are designed to produce the best outcomes across the largest number of children, and for most children most of the time, they do exactly that.

The question that remains unanswered is what happens at the individual level for the children who are not immunologically average at the moment of intervention.

A child whose gut microbiome developed through vaginal delivery and breastfeeding in a stable early environment is not immunologically equivalent to a child born by cesarean section, formula-fed, and sitting in a pediatric office in the early stage of an undetected viral infection. The immune landscape in those two children at eight weeks is genuinely different in ways that are measurable if you measure them. The schedule does not ask.

There is no standard clinical assessment of immune readiness before vaccination. No measurement of baseline inflammatory tone, gut-immune integrity, barrier function, or early antibody reactivity patterns. We administer the same protocol to all of them and measure outcomes at the population level, where the signal from any individual response pattern is too small to see.

My 74-year-old patient has an immune system that has been operating for seven decades and has lost its regulatory precision over time. We could see the functional consequence of that on his brain map before we knew the cause. Children at two months, four months, six months, have immune systems that have not yet completed their initial calibration. They are in the process of learning what is self and what requires a response, while simultaneously navigating the microbiome they are developing, the environment they were born into, and whatever immune stimuli arrive from outside.

The 74-year-old and the two-month-old are not the same clinical situation. But they share a common vulnerability. When the immune system loses precision, or when it has not yet established it, the brain is one of the primary places that shows up.

What This Means Clinically

I have been tracking functional immunity in this practice for years and gut-immune function for the better part of a decade. The conclusion I keep arriving at from every direction is consistent: when the immune system is disorganized, deficient, or poorly regulated, the brain reflects it. Not occasionally. Consistently.

The patients I see with the most complex and unexplained neurological presentations almost always have immune findings underneath them when we look. Antibodies directed at neural tissue. Gut-immune disruption feeding systemic inflammation that crosses into the central nervous system. Infections the immune system never fully resolved, maintaining ongoing immune activation for years.

PANDAS showed us this mechanism in children. Autoimmune encephalitis research has shown us this mechanism in adults. The neural antibody panel on my 74-year-old patient is showing us the same mechanism expressed quietly, gradually, and mislabeled as aging. In each of those cases, the functional disruption was measurable on brain mapping and clinical testing. The origin required a different set of tools to find.

The immune system is not a separate department from the brain. It is one of the primary systems through which brain function is regulated over the entire lifespan, from the earliest weeks of development through the last decades of life.

The debate about vaccine scheduling, whatever its political dimensions, has opened a legitimate biological question. What do we actually know about individual immune function before we intervene in it? What tools would it take to know? And what would we find if we measured immune readiness the way we measure everything else, as a real, individual, testable variable?

We do not know the answers to those questions. We should. And the September announcements from HHS on neurodevelopmental disorders, autism spectrum research, and vaccine safety review may finally start pushing medicine in the direction of asking them seriously.

That is the conversation worth having. Not whether vaccines work. They do. But whether we understand the immune system well enough, at any age, to know who we are treating before we begin.

Based on what I see in this practice, we have a long way to go.

‍